Lonza invests CHF 400 million in ValaisTuesday, 25 September 2018
To offer complete product lifecycle management in one location for Ibex Solutions, Lonza invests CHF 400 million to expand its biopark in Visp.
Lonza has announced the addition of two new Ibex Solutions offerings to its 100,000 m2 (1.1 million ft2) biopark in Visp in the canton of Valais. The expansion includes drug substance development and drug substance and drug product manufacturing, which allows customers to manage the complete product lifecycle in one site. Advanced technology, single-use bioreactors and improved platform processes shorten time to clinic and to market, while innovative business models will increase predictability.
The two new Ibex Solutions, Ibex Design and Ibex Develop, are designed to meet the evolving needs of biotech companies with antibody therapies, from the preclinical stage through to commercialization.
Ibex Design and Ibex Develop will become operational from 2020 and provide a full range of manufacturing options from early development through to full commercialization. This expansion will create about 200 new work positions.
The HES-SO Valais/Wallis adapts its offer to fulfill industry needs
The HES-SO Valais/Wallis adapts its offer to fulfill the workforce requirements of Lonza on its Visp site. The university henceforth proposes a biotechnologies curriculum in German.
“We must stay in touch with the industrial world, with the economic world and make sure the courses we propose fulfill these needs as well as future needs”, says François Seppey, director of the HES-SO Valais/Wallis.